Supplement 1. Baseline character=
istics
of meta-analyses are included in the review
|
№ |
First author, year |
Country=
|
Field of
study |
Number =
|
Number =
|
Total
number of included patients |
Number =
of
included patients, min-max interval |
Modalit=
y |
Number =
of
articles with external validation |
Assessi=
ng
the risk of bias: tool, general risk assessment |
Risk of
publication bias, assessed by Egger's test |
Heterogeneity of studies I2 |
|
=
1 |
J.H. Yoon et al=
., 2023
[9] |
|
Diagnostics of malignant neoplasms of the
breast |
16 |
0 |
497 091 |
190–177882 |
=
Digital
mammography and tomosynthesis |
1 |
QUADAS-2, QUADAS-C, low risk |
|
High |
|
=
2 |
S.E.
Hickman et al., 2023 [10] |
|
Diagnostics of malignant neoplasms of the
breast |
14 |
0 |
185 252 |
|
=
Digital
mammography |
10 |
=
QUADAS-2,
high risk |
|
Low |
|
=
3 |
L.T. Thong et&n=
bsp;al.,
2023 [18] |
|
Diagnostics of malignant tumors of the lun=
gs |
26 |
|
150 721 |
|
CT (21), chest x-ray (4),
tomosynthesis (1) |
|
=
QUADAS-2,
high risk |
|
High |
|
=
4 |
X. Zheng et al.=
, 2022
[21] |
|
Staging of malignant neoplasms of the lung=
s |
19 |
2 |
2234 |
82–1176 |
CT (16), PET-CT (2), MRI (1) |
|
QUADAS-2, low risk |
|
High |
|
5 |
M. Liu et al., =
2023
[55] |
|
Diagnostics of malignant tumors of the lun=
gs |
14 |
No data |
5251 |
10–101<=
/span>8 |
CT |
|
=
QUADAS-2,
low risk |
|
High |
|
=
6 |
T. Sugibayashi
et al., 2023 [17] |
|
=
Diagnostics of pneumot=
horax |
63 |
No data |
|
100–538390 |
Chest x-ray |
32 |
=
PROBAST,
high risk |
high |
|
|
=
7 |
R.Y.L.Kuo
et al., 2022 [11] |
|
=
Diagnostics of fractur=
es |
32 |
No data |
|
65–21456 |
CT (2), radiography (30) |
4 |
=
PROBAST,
high risk |
Low |
High |
|
=
8 |
X. Zhang et al.=
, 2022
[16] |
|
=
Diagnostics
of fractures |
39 |
No data |
464 478 |
50–327612 |
CT (5), radiography (34) |
|
=
QUADAS-2,
low risk |
Low |
High |
|
=
9 |
J.R. Lex et al.=
, 2023
[13] |
|
=
Diagnostics of fractur=
es |
39 |
No data |
714 939 |
64–7337 |
Radiography (RG) |
1 |
not assessed |
|
High |
|
=
10 |
P. Potipimpanon
et al., 2022 [32] |
|
=
Diagnostics of thyroid
nodules |
25 |
9 |
53960 |
50–42952 |
=
Ultrasonography
(US) |
|
=
QUADAS-2,
low risk |
Low |
High |
|
=
11 |
C.A.
Campello et al, 2023 [30] |
|
Diagnostics of malignant liver tumors |
20 |
4 |
|
|
US, Contrast-enhanced US |
2 |
=
QUADAS-2,
high risk |
High |
High |
|
=
12 |
F. Nabizadeh
et al., 2023 [46] |
|
=
Diagnostics of multiple
sclerosis |
41 |
No data |
5989 |
19–1155 |
MRI |
|
=
QUADAS-2,
low risk |
|
High |
|
=
13 |
M. Din et al., =
2023
[25] |
|
=
Diagnostics of cerebral
aneurysms |
43 |
2 |
18 143 |
|
CT, MRI, digital subtraction angiography |
6 |
=
QUADAS-2,
high risk |
|
High |
|
=
14 |
M.D.
Jшrgensen
et al., 2023 [56] |
EU |
=
Diagnostics of brain
metastases |
8 |
4 |
380 382 |
|
MRI |
4 |
=
QUADAS-2,
low risk |
|
High |
|
=
15 |
H.Y. Kim et al.=
, 2021
[43] |
|
=
Diagnostics
of brain metastases |
7 |
0 |
485 |
|
MRI |
0 |
=
QUADAS-2,
low risk |
Low |
Low |
|
=
16 |
A. Adamou et al=
., 2023
[45] |
EU |
=
Diagnostics of strokes=
|
11 |
No data |
1815 |
50–602 |
CT |
|
=
QUADAS-2,
low risk |
Low |
High |
|
=
17 |
S. Agarwal et a=
l., 2023
[22] |
|
=
Diagnostics of intracr=
anial
hemorrhages |
16 |
No data |
26164 |
|
CT, MRI |
|
=
QUADAS-2,
high risk |
|
High |
|
=
18 |
S.
Bedrikovetski et al., 2021a [23] |
|
Lymph node staging at colore=
ctal
cancer |
17 |
No data |
|
|
CT, MRI |
|
=
QUADAS-2,
low risk |
Low |
High for
radiomics; high for AI |
|
=
19 |
S. Soffer et al=
., 2023
[36] |
|
=
Detection
of pulmonary embolism |
5 |
0 |
36847 |
121–29465 |
|
|
=
QUADAS-2,
high risk |
|
High |
|
=
20 |
C. Yang et al.,=
2022
[40] |
|
Image segmentation for diagnostics of cerv=
ical
malignancy |
14 |
0 |
|
|
CT |
4 |
=
TRIPOD,
high risk |
Low |
Low in 2 case=
s;
high in 1 case |
|
=
21 |
L. Gao et al., =
2021
[14] |
|
=
Diagnostics of osteopo=
rosis |
7 |
2 |
3186 |
70–1268 |
|
|
=
QUADAS-2,
low risk |
Low |
High |
|
=
22 |
R. Rescinito
et al., 2023 [33] |
EU |
Diagnostics of the risk of intrauterine gr=
owth
retardation |
10 |
3 |
11800 |
46–6004 |
US, MRI |
|
=
JBI,
CASP, low risk |
Low |
Low |
|
=
23 |
Q. Wang et al.,=
2022
[29] |
|
Diagnostics of Covid-2019 |
32 |
No data |
59078 |
23–2800 |
CT |
|
=
QUADAS-2,
low risk |
High |
High |
|
=
24 |
T.N. Poly et al=
., 2021
[15] |
|
Diagnostics of Covid-2019 |
16 |
No data |
5896 |
|
CT (8), RG (8) |
0 |
=
QUADAS-2,
high risk |
|
|
|
=
25 |
T.E.
Komolafe et al., 2023 [28] |
|
Diagnostics of Covid-2019 |
19 |
No data |
|
|
CT |
|
=
QUADAS-2,
medium risk |
Low |
High |
|
=
26 |
F. Abesi et al.=
, 2023
[34] |
|
Diagnostics and segmentation of oral and
maxillofacial structures |
19 |
No data |
|
|
Cone beam CT |
2 |
not assessed |
High |
High |
|
=
27 |
F.F. Badr, F.M.=
Jadu,
2022 [35] |
Saudi Arabi |
Diagnostics and segmentation of oral and
maxillofacial structures |
13 |
No data |
|
|
Cone beam CT |
1 |
=
|
High |
|
|
=
28 |
W. Xing et al.,=
2023
[20] |
|
Response to therapy at lung malignancies |
18 |
0 |
4719 |
|
CT (8), PET (3), PET-CT (6), MRI (1) |
|
=
QUADAS-2,
NOS, low risk |
High |
High |
|
=
29 |
N. Menon et al.=
, 2023
[19] |
|
Response to therapy at malignant neoplasms=
of
the esophagus |
12 |
No data |
443 |
|
PET-CT |
|
not assessed |
|
High |
|
=
30 |
B.G.
Taib et al., 2023 [39] |
|
Burns: depth estimation, segmentation,
mortality prediction |
12 |
No data |
|
|
=
|
|
=
QUADAS-2,
high risk |
|
High |
|
=
31 |
S. Sadr. et al.=
, 2023
[27] |
|
Periapical lesions: detection, segmentatio=
n,
classification |
6 |
0 |
|
|
RG, Cone beam CT |
|
=
QUADAS-2,
low risk |
Low |
High |
|
=
32 |
M. Islam et al.=
, 2022
[37] |
|
Diagnostics of malignant neoplasms of the
esophagus |
28 |
No data |
703 006 |
14–15286 |
Endoscopy |
5 |
not assessed |
Low |
High |
|
=
33 |
K. Evangelista
et al., 2022 [57] |
|
Decision of tooth removing |
6 |
No data |
1732 |
|
=
|
|
=
QUADAS-2,
medium risk |
|
High |
|
=
34 |
Y. Xue et al., =
2022
[12] |
|
Differentiation of benign and malignant
thyroid nodules |
25 |
7 |
17429 |
91–7216 |
US |
|
=
QUADAS-2,
medium risk |
Low |
High |
|
=
35 |
H.L. Xu et=
al.,
2022 [26] |
|
Diagnostics of malignant neoplasms of the
ovaries |
34 – to=
tal;
|
|
117 625 |
20–1076=
24 |
US (19), MRI (10), CT (3) |
|
QUADAS-AI (modified QUADAS-2), high risk |
Low |
High |
|
36 |
E.A. Dumitrescu=
et al.,
2022 [31] |
EU |
Diagnostics of malignant neoplasms of the
pancreas |
10 |
2 |
1871 |
35–583 |
US |
|
=
QUADAS-2,
low risk |
|
Low |
|
=
37 |
S.
Bedrikovetski et al., 2021b [24] |
|
Diagnostics of metastases to the lymph nod=
es
in patients with malignant neoplasms of the abdominal cavity |
21– tot=
al; |
5 |
6046 |
17–765<= o:p> |
CT (10), MRI (10) |
|
QUADAS-2, high risk |
Low |
низкая=
- радиоло=
ги; высокая=
- радиоми=
ка |
|
38 |
Y. Xu et al., 2=
021 [38] |
|
=
Detection
of colorectal polyps |
13 |
No data |
|
|
=
Endoscopy |
|
=
QUADAS-2,
medium risk |
Low |
High |